Guardian Technologies Announces Extension of USC Collaboration to Develop Clinical Protocols and Advanced Prototype for Signature Mapping.

Prototype to Provide Model for Company's Advanced Disease Detection Technology Targeting Multibillion Dollar Healthcare Market

HERNDON, Va. -- Guardian Technologies International (OTCBB: GDTI), innovators of groundbreaking medical imaging and threat detection technology with critical and immediate applications for the healthcare and homeland security markets, announced today that the Medical Imaging and Informatics Laboratory at the University of California (USC) has extended its collaboration agreement with the Company to further validate the real world application of Signature Mapping[TM] and to develop a prototype that will serve as a model for future use by radiologists.

Clinical evaluation and initial prototype development will be led by Dr. H.K. Huang, Professor of Radiology and Biomedical Engineering at USC. Dr. Huang and his team will be evaluating feedback provided by radiologists regarding potential enhancements to Signature Mapping visualization tools and integration methodology as it applies to medical radiological imaging workflow.

"We believe that working with Dr. Huang and his world-class team at USC provides further validation for Signature Mapping and takes us one step closer to delivering the promise of our technology to radiologists around the world," said Bill Donovan, President and Chief Operating Officer of Guardian Technologies International. "This agreement is yet another example of Guardian's continued mission to commercialize Signature Mapping as a primary means of building exceptional value for our shareholders."

According to the agreement, Guardian and USC will collaborate on three distinct areas: breast imaging and breast cancer research; chest imaging and tuberculosis detection and monitoring; and traumatic brain injury and acute intracranial brain hemorrhaging.

Focusing on breast imaging and breast cancer detection, USC will provide continued analytical validation of Signature Mapping as it relates to the recently announced success from the South Florida mammography database. USC will also focus on the development and evaluation of a clinical prototype for use in mammography for the visualization of breast cancer and study the integrated use of MRI and mammography as an effective screening and diagnostic tool.

USC will also support the development and evaluation of a prototype for use in screening, monitoring and staging after the detection of tuberculosis. USC's clinical focus will be on chest x-rays, either from direct digital or scanned film.

Furthermore, USC will apply its efforts towards Signature Mapping's application to acute traumatic brain injury with the development and evaluation of a prototype for use in detection and quantification of acute intracranial hemorrhage, with primary deployment on CT scanners. USC will also assess how the current work in multiple sclerosis and normal pressure hydrocephalus can be used for patient screening and evaluation in traumatic brain injury work that was jointly conducted last year.

Signature Mapping is protected by a robust patent portfolio. Guardian has already undertaken research, development and clinical evaluation on challenges ranging from more precise and earlier detection of breast and prostate cancer. Research has also proven that Signature Mapping can automatically detect intracranial hemorrhagic associated with traumatic brain injuries using CTs, and can locate and quantify multiple sclerosis lesions in MRIs, as well as the extent of tuberculosis, pneumoconiosis, and even cancer in the lungs using commonly available and inexpensive chest x-rays.

About Guardian Technologies International

The impact of Guardian's industry-first computer aided detection technologies are immediate and profound for helping to eliminate human error in both the Homeland Security and the Medical Industry sectors. The Company's software solutions can be seamlessly installed to complement existing imaging devices, such as baggage scanners and medical MRI, to scan the contents of any image and immediately identify items of interest not easily discernable by the human eye.

* Airport Security: Guardian's technology complements and enhances current-generation baggage x-ray scanners with the ability to automatically and effectively detect, locate, and identify explosives and other types of threats.

* Disease Identification: Existing medical imaging devices used in Computer Aided Detection (CAD) are further improved with Guardian's auto-diagnostic ability to detect anomalous tissue (e.g., tumors) and other potential disease states or conditions.

* Technology-Independence: Because Guardian's technologies utilize and process the actual image output generated by the original imaging systems, virtually any existing or future imaging device can be upgraded with Guardian's products, delivering an instant, multibillion-dollar potential customer base with no competition.

Guardian's technology and product development partnerships include a Cooperative Research and Development Agreement (CRDA) with the U.S. Department of Homeland Security - Science and Technology Directorate. The Company's platform and product suite is protected by a robust patent portfolio. They are also ramping up new technologies and plan to acquire complimentary technologies to accelerate the Company's high-growth business model.

For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/guardian.

To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/guardian/quote.html.

To view an investor fact sheet about the company, visit http://www.trilogy-capital.com/tcp/guardian/factsheet.html.

Forward-Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements in this document and those made from time to time by Guardian through its senior management are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's current views with respect to the future events or financial performance discussed in this release, based on management's beliefs and assumptions and information currently available. When used, the words "believe," "anticipate," "estimate," "project," "should," "expect," "plan," "assume" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Forward-looking statements concerning future plans or results are necessarily only estimates and actual results could differ materially from expectations. Certain factors that could cause or contribute to such differences include, among other things, in particular, the size and timing of contract awards, performance on contracts, performance of acquired companies, availability and cost of key components, unanticipated results from audits of the financial results of the Company and acquired companies, changing interpretations of generally accepted accounting principles, outcomes of government reviews, developments with respect to litigation to which we are a party, potential fluctuations in quarterly results, dependence on large contracts and a limited number of customers, lengthy sales and implementation cycles, market acceptance of new or enhanced products and services, proprietary technology and changing competitive conditions, system performance, management of growth, dependence on key personnel, ability to obtain project financing, general economic and political conditions and other factors affecting spending by customers, the unpredictable nature of working with government agencies and other risks, uncertainties and factors including those described from time to time in Guardian's filings with the Securities and Exchange Commission, including without limitation, Guardian's Form 10-K for the year ended December 31, 2006, and its quarterly reports on Form 10-Q. Guardian expressly disclaims any obligation to update any forward-looking statements.